UY36722A - Composición de péptidos múltiples. - Google Patents

Composición de péptidos múltiples.

Info

Publication number
UY36722A
UY36722A UY0001036722A UY36722A UY36722A UY 36722 A UY36722 A UY 36722A UY 0001036722 A UY0001036722 A UY 0001036722A UY 36722 A UY36722 A UY 36722A UY 36722 A UY36722 A UY 36722A
Authority
UY
Uruguay
Prior art keywords
peptides
composition
combination
multiple peptides
relates
Prior art date
Application number
UY0001036722A
Other languages
English (en)
Inventor
Peakman Mark
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of UY36722A publication Critical patent/UY36722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La invención se refiere a una combinación específica de péptidos. La combinación de péptidos puede estar presente en una composición farmacéuticamente aceptable. La combinación de péptidos puede se utilizada en la terapia o prevención de la Diabetes de Tipo 1 (T1D). La invención también se refiere a un método de diagnóstico o de determinación de eficacia del tratamiento, el método utilizando la combinación específica de péptidos.
UY0001036722A 2015-06-10 2016-06-10 Composición de péptidos múltiples. UY36722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510056.3A GB201510056D0 (en) 2015-06-10 2015-06-10 Multi-peptide composition

Publications (1)

Publication Number Publication Date
UY36722A true UY36722A (es) 2017-01-31

Family

ID=53785229

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036722A UY36722A (es) 2015-06-10 2016-06-10 Composición de péptidos múltiples.

Country Status (26)

Country Link
US (1) US11400131B2 (es)
EP (1) EP3307298B1 (es)
JP (1) JP6969790B2 (es)
KR (1) KR20180023948A (es)
CN (1) CN107896494B (es)
AR (1) AR104947A1 (es)
AU (1) AU2016275295B2 (es)
BR (1) BR112017026537A2 (es)
CL (1) CL2017003143A1 (es)
CO (1) CO2017012986A2 (es)
EA (1) EA201890007A1 (es)
EC (1) ECSP18001655A (es)
ES (1) ES2778630T3 (es)
GB (1) GB201510056D0 (es)
HK (1) HK1253094A1 (es)
IL (1) IL256199B2 (es)
MA (1) MA41668A1 (es)
MX (1) MX2017015658A (es)
PE (1) PE20180450A1 (es)
PH (1) PH12017501918A1 (es)
PL (1) PL3307298T3 (es)
TN (1) TN2017000517A1 (es)
TW (1) TW201712027A (es)
UY (1) UY36722A (es)
WO (1) WO2016198887A1 (es)
ZA (1) ZA201707873B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542488A (ja) * 1999-04-21 2002-12-10 ザイコス インク． 疾患を促進するｃｄ４＋ｔリンパ球によって認識されるペプチドエピトープ
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
GB0402129D0 (en) * 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
EP1709070B1 (en) * 2004-01-30 2013-05-29 King's College London Peptides for treatment of autoimmune diseases
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
WO2008083331A2 (en) * 2006-12-29 2008-07-10 The Regents Of The University Of Colorado Diagnostic and therapeutic target for autoimmune diseases and uses thereof
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
CN104203263A (zh) * 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞

Also Published As

Publication number Publication date
WO2016198887A1 (en) 2016-12-15
HK1253094A1 (zh) 2019-06-06
AU2016275295B2 (en) 2021-12-09
EA201890007A1 (ru) 2018-05-31
EP3307298A1 (en) 2018-04-18
CA2984957A1 (en) 2016-12-15
AU2016275295A1 (en) 2017-12-07
JP6969790B2 (ja) 2021-11-24
CN107896494B (zh) 2021-09-03
ECSP18001655A (es) 2018-10-31
IL256199B2 (en) 2024-11-01
US11400131B2 (en) 2022-08-02
TN2017000517A1 (en) 2019-04-12
US20180221434A1 (en) 2018-08-09
CN107896494A (zh) 2018-04-10
JP2018524301A (ja) 2018-08-30
GB201510056D0 (en) 2015-07-22
PE20180450A1 (es) 2018-03-05
ES2778630T3 (es) 2020-08-11
PH12017501918A1 (en) 2018-03-19
IL256199A (en) 2018-02-28
AR104947A1 (es) 2017-08-23
IL256199B1 (en) 2024-07-01
KR20180023948A (ko) 2018-03-07
TW201712027A (zh) 2017-04-01
MX2017015658A (es) 2018-08-15
BR112017026537A2 (pt) 2019-11-12
CO2017012986A2 (es) 2018-03-09
PL3307298T3 (pl) 2020-06-29
CL2017003143A1 (es) 2018-05-18
EP3307298B1 (en) 2020-01-15
ZA201707873B (en) 2019-05-29
MA41668A1 (fr) 2018-03-30

Similar Documents

Publication Publication Date Title
MX392028B (es) Vacunas para el tratamiento y prevención del cáncer.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
EA201990071A1 (ru) Композиция пептидной вакцины
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
WO2015112902A3 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
NZ700467A (en) Treatments suitable for malassezia infections
MX420767B (es) Proteina de union al factor h modificada
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
JP2017517561A5 (es)
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
ECSP18001655A (es) Composición de péptidos múltiples
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201791456A1 (ru) Пептиды-антагонисты cgrp
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221114